The American College of Rheumatology (ACR) updated its lupus nephritis (LN) treatment guidelines, emphasizing triple therapy with Benlysta or a calcineurin inhibitor. This shift impacts the potential role of Roche/Genentech’s Gazyva, an anti-CD20 monoclonal antibody anticipated to receive FDA approval for LN later this year. Spherix Global Insights’ market research indicates specialists plan to increase Benlysta and Lupkynis usage following these recommendations.
This guideline update is crucial for LN patients as it potentially improves treatment outcomes by promoting earlier and more aggressive interventions. The emphasis on triple therapy, particularly with readily available agents like Benlysta and Lupkynis, provides clinicians with clearer direction for managing newly diagnosed, flaring, or active Class III or IV ± V LN. The clarification regarding proteinuria levels for different classes of LN further refines treatment strategies, potentially leading to earlier and more targeted interventions. This could translate into better kidney outcomes and improved quality of life for patients.
The ACR guidelines conditionally recommend triple therapy (glucocorticoids, mycophenolate mofetil or cyclophosphamide, and either Benlysta or a calcineurin inhibitor) for most patients with active LN. For those with high proteinuria (≥3 g/g), the guidelines specifically recommend a calcineurin inhibitor like Lupkynis. While Gazyva shows promise, its role remains less defined, with the ACR suggesting its use primarily in patients who fail initial therapies. Despite this, significant anticipation exists for Gazyva’s approval, with many specialists expecting to incorporate it into their treatment algorithms. Market analysis suggests Gazyva may compete with Benlysta, and potentially rituximab, depending on the specialist’s perspective.
The updated ACR guidelines are likely to reshape the LN treatment landscape. Increased utilization of Benlysta and Lupkynis is anticipated, while the market entry of Gazyva will introduce a new dynamic, particularly for refractory cases. The interplay between these agents and the evolving treatment paradigm will be a critical area to monitor in the coming months. The ultimate impact will depend on real-world effectiveness, clinical experience, and how specialists integrate Gazyva into their practices.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
